Treatment recommendations are guided by consultation and may evolve over time
For example, t aking 1000mg 23 times a week is a common way for vegans to avoid a deficiency
FAQ BPC-157
LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
This product is supplied exclusively as a research-grade laboratory reagent and is not intended for human or animal use
4 Materials and methods 4.1 Cell culture and in vivo experiments 4.1.1 Cell lines Four human NB cell lines were used in this paper: Be(2)-C (MNA), IMR5-/75-shMYCN (29) (MNA, doxycycline-inducible shRNA targeting MYCN, resulting in MYCN downregulation), IMR-32 (MNA), and SH-SY5Y/6TR(EU)/pTrex-Dest-30/MYCN (non-MNA, doxycycline-inducible transgene, resulting in MYCN overexpression)